Femur length anomalies tend to decrease with later phenology (greater day of year of adulthood anomaly) regardless of elevation or species’ seasonal timing. by César R. Nufio (11646271)

The linearly decreasing convergence factor a. by Junhao Wei (6816803)

Average days (mean) to heal a wound in 2022 and 2023. by Heba Tallah Mohammed (2822432)

Mitigation (decreasing) scenario. by Fabio Correddu (12501799)

Predicting pattern diversity decreases as a function of and . by Selim Haj Ali (21222613)

“…(a) and (b): Average negative predictive value for and , respectively for and . …”

Claudin V is decreased following infection with Mtb. by Amanda S. Latham (12093638)

“…Representative images of the frontal cortex (A–D), cerebral nuclei (F–I), brain stem (K–N), thalamus (P–S), and hippocampus (U–X) 15 days post-infection are shown. …”

Pregnancy-induced decrease in maternal serum BUN and IFN- by Haruka Mizobuchi (5395394)

Sleep deprivation increased inflammatory cytokines and decreased corticosterone in the blood. by Weiran Shan (16969688)

HSP90 inhibition by RGRN-305 and 17-AAG decreased proinflammatory protein secretion. by Hakim Ben Abdallah (14578241)

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Heteroscedastic linear mixed model main results, estimating the volume (ml) of beer sold per day on the transformed (cube root) scale, on the original scale and on the relative sca... by Eleni Mantzari (6991172)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Tetrandrine decreases Mtb antigen presentation. by Elham Karamooz (2584474)

Selection frequencies plotted in decreasing order. by Hannah P. Rowe (7830599)